Both companies will cooperate in developing customized three-dimensional polymeric scaffolds to encapsulate pancreatic-derived spheroids, and in conducting a feasibility study...

Thanks to LAISOLID, ROVI is advancing in the development of long-acting injectable formulations capable of preserving the stability and efficacy...

With a total investment exceeding 80 million euros, LAISOLID addresses both the development of industrial processes and the creation of...

The LAISOLID project, developed by Laboratorios Farmacéuticos ROVI, has been granted €36.3 million in funding by the Centre for Technological...